Infliximab, a purified chimeric IgG monoclonal antibody protein, is created from recombinant DNA technology. It has both mouse and human components to effectively block the activity of tumor necrosis factor-alpha (TNF-α). Infliximab is used to stimulate the immune system of our body and treat certain diseases, including ulcerative colitis, active rheumatoid arthritis, and ankylosing spondylitis.
[1] This product is a certified reference material, consisting of a pure substance within an aqueous solvent solution, 12.5 mM histidine buffer. This standard is prepared and certified under the ISO 17034, ISO/IEC 17025, and ISO 9001 standards, meeting the requirements of a certified reference material and a primary standard per ISO guidelines. This primary standard is suitable to prepare calibrators and/or controls.